ASTRAZENECA aims to grow revenue by about 75 per cent to US$80 billion by 2030, it said on Tuesday (May 21), boosted by the expected launch of 20 new medicines and through growth in its existing oncology, biopharmaceuticals and rare disease portfolio.
AstraZeneca aims for US$80 billion in total revenue by 2030
Forbes 40under40 stands as a distinguished platform revered for its commitment to honoring and applauding the remarkable achievements of exceptional individuals who have yet to reach the age of 40. This esteemed initiative serves as a beacon of inspiration, spotlighting trailblazers across various industries and domains, showcasing their innovation, leadership, and impact on a global scale.
© 2024 Forbes 40under40. All Rights Reserved.